Talphera Inc. (TLPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Talphera Inc. (TLPH) has a cash flow conversion efficiency ratio of -0.143x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.44 Million) by net assets ($17.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Talphera Inc. balance sheet independence to measure how much of total assets are equity-financed.
Talphera Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Talphera Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Talphera Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Talphera Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Talphera Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regal Holding Co Ltd
TW:4807
|
-0.239x |
|
Ralco Agencies Ltd
TA:RLCO
|
0.141x |
|
MODULIGHT OY EO 1
F:78W
|
0.019x |
|
ABO Group
BR:ABO
|
0.158x |
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
N/A |
|
Scilex Holding Company
NASDAQ:SCLX
|
0.004x |
|
Lion Chemtech Co. Ltd
KQ:171120
|
-0.035x |
|
Caprice Resources Limited
F:C3F
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Talphera Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Talphera Inc. from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see TLPH company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.04 Million | $-11.36 Million | -0.667x | +57.92% |
| 2024-12-31 | $8.00 Million | $-12.68 Million | -1.585x | -27.82% |
| 2023-12-31 | $14.11 Million | $-17.49 Million | -1.240x | +4.51% |
| 2022-12-31 | $21.81 Million | $-28.33 Million | -1.299x | -255.38% |
| 2021-12-31 | $-35.89 Million | $-30.00 Million | 0.836x | +21.02% |
| 2020-12-31 | $-55.75 Million | $-38.51 Million | 0.691x | -44.11% |
| 2019-12-31 | $-41.42 Million | $-51.18 Million | 1.236x | +118.08% |
| 2018-12-31 | $4.25 Million | $-29.07 Million | -6.836x | -938.53% |
| 2017-12-31 | $-36.51 Million | $-29.77 Million | 0.815x | -85.20% |
| 2016-12-31 | $-5.34 Million | $-29.39 Million | 5.508x | +1014.04% |
| 2015-12-31 | $33.11 Million | $-19.95 Million | -0.603x | +18.41% |
| 2014-12-31 | $46.66 Million | $-34.46 Million | -0.739x | -10994.20% |
| 2013-12-31 | $73.16 Million | $-487.00K | -0.007x | +99.08% |
| 2012-12-31 | $33.85 Million | $-24.58 Million | -0.726x | +17.01% |
| 2011-12-31 | $17.47 Million | $-15.29 Million | -0.875x | -571.70% |
| 2010-12-31 | $-65.89 Million | $-12.22 Million | 0.186x | -49.37% |
| 2009-12-31 | $-52.99 Million | $-19.42 Million | 0.366x | -35.38% |
| 2008-12-31 | $-33.34 Million | $-18.90 Million | 0.567x | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more